Alembic Pharmaceuticals yesterday received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Entacapone Tablets USP, 200 mg. The approved ANDA is therapeutically equivalent to the Reference Listed Drug (RLD) product Comtan tablets, 200 mg, of Orion Corporation, a statement from the company informed.
It said that Entacapone tablets are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose “wearing-off” in patients with Parkinson’s disease.
Entacapone tablets USP, 200 mg have an estimated market size of $10.5 million for twelve months ending September 2021, according to IQVIA.